Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 6423 | Ordered by Date (descending)
1 2 3 ... 63 64 65  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Oncorus–Cowen: investment, 201908 financing round Series B totalling $79.5m incl co-lead investor Cowen Healthcare Investments 2019-08-21
Oncorus–Perceptive Advisors: investment, 201908 financing round Series B totalling $79.5m incl co-lead investor Perceptive Advisors 2019-08-21
Oncorus–SEVERAL: investment, 201908 financing round Series B $79.5m co-led by Cowen Healthcare Investments + Perceptive Advisors 2019-08-21
Bayer–Elanco: investment, 201908– acquisition of Bayer Animal Health business for $5.3b in cash + $2.3b in shares 2019-08-20
Juvenescence–SEVERAL: investment, 201908 financing round Series B $100m incl founders + private investment companies 2019-08-19
Synpromics–AskBio: investment, 201908 acquisition of Synpromics Ltd by Asklepios Biopharmaceutical Inc 2019-08-13
Boehringer–Univ Texas: cancer drugs, 201908– collab new virtual r+d center to advance new cancer therapies incl KRAS inhibitors + TRAILR2 agonists 2019-08-12
Cavion–Jazz Pharmaceuticals: investment, 201908 acquisition $52.5m upfront + $260m milestones of Cavion Inc by Jazz 2019-08-12
Curetis–HC Wainwright: investment banking, 201908– supply service Curetis retains HC Wainwright to evaluate all strategic options 2019-08-12
BlueRock Therapeutics–Bayer: investment, 201808– acquisition 100% by acquiring remaining 59.2% for $240m upfront + $360m milestones 2019-08-08
MeiraGTx–SEVERAL: investment, 201908 public offering $75.2m+$11.28m with 3.2m+480k ordinary shares at $23.5/share 2019-08-07
Stemline Therapeutics–SEVERAL: investment, 201908 public offering $76.25m+$11.44m with 5m+575k shares common stock at $15.25/share 2019-08-07
Blue Heron–Eurofins: investment, 201908 acquisition of Blue Heron Biotech by Eurofins Genomics LLC 2019-08-06
GNA Biosolutions–GreyBird Ventures: investment, 201908 financing round Series C totalling $13.5m incl new investor GreyBird Ventures 2019-08-05
GNA Biosolutions–SEVERAL: investment, 201908 financing round Series C $13.5m from new + existing EU + US investors 2019-08-05
Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP 2019-07-31
Atlantic Healthcare–Lazar Partners: public relations, 201907 service existent US IR + media relations by Lazar Partners 2019-07-31
Wellington Partners–SEVERAL: investment, 201907 final closing €210m WPLS-V fund incl investors KfW Capital + Talanx + UTIMCO + Univ Texas + EIB 2019-07-31
Wellington Partners–Univ Texas: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Univ Texas/Texas A&M Investment Company 2019-07-31
Wellington Partners–UTIMCO: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor UTIMCO 2019-07-31
Genomic Health–Exact Sciences: investment, 201907– merger acquisition $2.8b at $72/share with $1.07b in cash + $1.73b in shares ANNOUNCED 2019-07-29
908 Devices–Manufacturing USA: grant, 201907– grant from NIIMBL for developm of at-line bioreactor process analytics tog w MilliporeSigma et al 2019-07-25
Breath Therapeutics–Zambon: investment, 201907 acquisition €140m + €360m milestones by Zambon 2019-07-25
Castle Biosciences–SEVERAL: investment, 201907 IPO $64m priced at $16/share 2019-07-25
Merck (DE)–908 Devices: biopharma production technology, 201907– collab 908 + MilliporeSigma + Univ North Carolina on bioreactor process analytics 2019-07-25
Twist Bioscience–Imagene: nucleic acid storage technology, 201907– supply service DNA encapsulation using DNAshell technology 2019-07-25
Freenome–Polaris Partners: investment, 201907 financing round Series B totalling $160m incl new + co-lead investor Polaris Partners 2019-07-24
Freenome–RA Capital Management: investment, 201907 financing round Series B totalling $160m incl new + co-lead investor RA Capital Management 2019-07-24
Freenome–Roche: investment, 201907 financing round Series B totalling $160m incl new + co-investor Roche Venture Fund 2019-07-24
Freenome–SEVERAL: investment, 201907 financing round Series B $160m co-led by RA Capital Management + Polaris Partners + incl Roche Venture Fund 2019-07-24
Freenome–W2O Group: public relations, 201907 service existent by Pure Communications 2019-07-24
Genmab–SEVERAL: investment, 201907 US IPO $581.6m with 28.5m+4.275m ADSs at $17.75/ADS with 10 ADSs/share at Nasdaq Global Select Market 2019-07-22
AvroBio–SEVERAL: investment, 201907 underwritten public offering $138.3m with 6.5m+975k shares common stock 2019-07-19
Gilead–Novartis: virostatic agents, 201907– license excl ww for three preclinical antivirals incl upfront payment plus $291m milestones + royalties 2019-07-19
Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Boehringer–Bridge Biotherapeutics: autotaxin inhibitor, 201907– collab + ww license BBT-877 up to €45m upfront/near-term + up to €1.1b + royalties 2019-07-18
Fulcrum Therapeutics–SEVERAL: investment, 201907 IPO $72m priced at $16/share 2019-07-18
Mallinckrodt–Silence Therapeutics: RNAi drugs, 201907– collab developm + commercialisation $20m upfront + milestones + royalties plus $5m investment 2019-07-18
Mirum Pharmaceuticals–SEVERAL: investment, 201907 IPO $75m priced at $15/share 2019-07-18
MIT–Merck (DE): CRISPR technology, 201907– collab pooling of IP from Merck + Broad Institute for licensing CRISPR for r+d by Broad 2019-07-18
Silence Therapeutics–Mallinckrodt: investment, 201907 investment £4m with 5m new ordinary shares at 79p/share as part of collab = 6.5% share 2019-07-18
Pyxis Oncology–Agent Capital: investment, 201907 financing round Series A totalling $22m incl co-investor Agent Capital 2019-07-17
Pyxis Oncology–Bayer: investment, 201907 financing round Series A totalling $22m incl lead investor Leaps by Bayer 2019-07-17
Pyxis Oncology–Ipsen: investment, 201907 financing round Series A totalling $22m incl co-investor Ipsen 2019-07-17
Pyxis Oncology–Longwood Fund: investment, 201907 financing round Series A totalling $22m incl co-investor Longwood Fund 2019-07-17
Pyxis Oncology–SEVERAL: investment, 201907 financing round Series A $22m led by Leaps by Bayer 2019-07-17
Bayer–Evogene: plant genomics, 201907 collaboration amendment to refocus on genome editing target discovery for corn diseases 2019-07-16
Roche–Sosei: GPCR-targeting drugs, 201907– collab multi-target research + licensing up to >$1b Genentech + Sosei Heptares 2019-07-16
Recursion Pharmaceuticals–SEVERAL: investment, 201907 financing round Series C $121m led by Baillie Gifford 2019-07-15
Galapagos–Gilead: investment, 201907 equity investment $1.1b at €140.59/share raising share from 12.3% to 22% as part of collab 2019-07-14
Gilead–Galapagos: drug research + development, 201907–202906 strategic 10y collab $3.9b upfront + $1.1b equity investment + milestones 2019-07-14
BioTek Instruments–Agilent: investment, 201907– acquisition $1.165b incl anticipated tax benefits net $1.05b 2019-07-11
BioNTech–BVCF Management: investment, 201907 financing round Series B totalling $325m incl co-investor BVCF Management 2019-07-09
BioNTech–Fidelity: investment, 201907 financing round Series B totalling $325m incl existing + lead investor Fidelity Management and Research 2019-07-09
BioNTech–Invus Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investor Invus 2019-07-09
BioNTech–Jebsen Capital: investment, 201907 financing round Series B totalling $325m incl co-investor Jebsen Capital 2019-07-09
BioNTech–Mirae Asset: investment, 201907 financing round Series B totalling $325m incl co-investor Mirae Asset Financial Group 2019-07-09
BioNTech–Platinum Asset Management: investment, 201907 financing round Series B totalling $325m incl co-investor Platinum Asset Management 2019-07-09
BioNTech–Redmile Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investor Redmile Group 2019-07-09
BioNTech–SEVERAL: investment, 201907 financing round Series B $325m led by existing investor Fidelity Management and Research 2019-07-09
BioNTech–Steam Athena Capital: investment, 201907 financing round Series B totalling $325m incl co-investor Steam Athena Capital 2019-07-09
BioNTech–Strüngmann Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investorStrüngmann Family Office 2019-07-09
JnJ–Celsius Therapeutics: biomarker discovery, 201907– collab to identify biomarkers for ulcerative colitis with Janssen Biotech Inc 2019-07-09
Revolution Medicines–BVF Partners: investment, 201907 financing round Series C totalling $100m incl co-investor Biotechnology Value Fund 2019-07-09
Revolution Medicines–Casdin Capital: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Casdin Capital 2019-07-09
Revolution Medicines–Column Group: investment, 201907 financing round Series C totalling $100m incl existing + co-investor The Column Group 2019-07-09
Revolution Medicines–Cormorant Asset Management: investment, 201907 financing round Series C totalling $100m incl co-investor Cormorant Capital 2019-07-09
Revolution Medicines–Deerfield Management: investment, 201907 financing round Series C totalling $100m incl co-investor Deerfield Management 2019-07-09
Revolution Medicines–Fidelity: investment, 201907 financing round Series C totalling $100m incl co-investor Fidelity Management and Research Company 2019-07-09
Revolution Medicines–Guggenheim: financial services, 201907 supply service strategic advice for $100m Series C round by Guggenheim Securities 2019-07-09
Revolution Medicines–Latham & Watkins: legal services, 201907 supply service legal counsel with regard to $100m Series C financing round 2019-07-09
Revolution Medicines–Nextech Invest: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Nextech Invest 2019-07-09
Revolution Medicines–Schroders: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Schroder Adveq 2019-07-09
Revolution Medicines–SEVERAL: investment, 201907 financing round Series C $100m led by Boxer Capital 2019-07-09
Revolution Medicines–Tavistock: investment, 201907 financing round Series C totalling $100m incl lead investor Boxer Capital 2019-07-09
Revolution Medicines–Third Rock Ventures: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Third Rock Ventures 2019-07-09
Revolution Medicines–Vida Strategic Partners: public relations, 201907 service PR + IR existent by Vida Strategic Partners 2019-07-09
Revolution Medicines–Vivo Capital: investment, 201907 financing round Series C totalling $100m incl co-investor Vivo Capital 2019-07-09
IGM Biosciences–Argot Partners: public relations, 201907 service existent by Argot Partners 2019-07-08
IGM Biosciences–Haldor Topsøe: investment, 201907 financing round Series C totalling $102m incl existing + founding investor Haldor Topsøe Holding A/S 2019-07-08
IGM Biosciences–Janus Henderson: investment, 201907 financing round Series C totalling $102m incl new investor Janus Henderson Investors 2019-07-08
IGM Biosciences–Redmile Group: investment, 201907 financing round Series C totalling $102m incl new investor Redmile Group 2019-07-08
IGM Biosciences–SEVERAL: investment, 201907 financing round Series C $102m incl Redmile Group + Janus Henderson + Vivo Capital et al 2019-07-08
IGM Biosciences–Vivo Capital: investment, 201907 financing round Series C totalling $102m incl new investor Vivo Capital 2019-07-08
PMOD Technologies–Bruker Corp: investment, 201907 acquisition €na of PMOD Technologies LLC by Bruker 2019-07-08
Danaher–Cobo Technologies: protein expression analysis, 201907– collab co-marketing PIPPR platform with SWATH Acquisition + Sciex TripleTOF 6600 2019-07-05
Oncovita–Institut Pasteur: cancer immunotherapy, 201907– license excl ww €na for use of oncolytic measles virus platform for product developm + sale 2019-07-02
Antimicrobials Working Group–Amplyx Pharmaceuticals: antibiotics, 201907– collab existent Amplyx is member of AWG 2019-07-01
Antimicrobials Working Group–Aridis Pharmaceuticals: antibiotics, 201907– collab existent Aridis is member of AWG 2019-07-01
Antimicrobials Working Group–Cidara Therapeutics: antibiotics, 201907– collab existent Cidara is member of AWG 2019-07-01
Antimicrobials Working Group–ContraFect: antibiotics, 201907– collab existent ContraFect Corp is member of AWG 2019-07-01
Antimicrobials Working Group–Entasis Therapeutics: antibiotics, 201907– collab existent Entasis is member of AWG 2019-07-01
Antimicrobials Working Group–Iterum Therapeutics: antibiotics, 201907– collab existent Iterum is member of AWG 2019-07-01
Antimicrobials Working Group–X-Biotix Therapeutics: antibiotics, 201907– collab X-Biotix becomes member of AWG 2019-07-01
Century Therapeutics–Bayer: investment, 201907 financing round totalling $250m commitments incl $215m from Leaps by Bayer 2019-07-01
Century Therapeutics–Fujifilm: investment, 201907 financing round totalling $250m commitments incl co-investor Fujifilm Cellular Dynamics Inc 2019-07-01
Century Therapeutics–SEVERAL: investment, 201907 financing round $250m commitments from Leaps by Bayer + Versant Ventures + Fujifilm CDI 2019-07-01
Century Therapeutics–Versant Ventures: investment, 201907 financing round totalling $250m commitments incl existing + co-investor Versant Ventures 2019-07-01
1 2 3 ... 63 64 65  next pagenext page



Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

» top